Serum Homocysteine Levels And Correlation With Comorbidities In Patients With Severe Plaque Psoriasis

Objective:To analyze whether the homocysteine level of 141 patients with severe plaque psoriasis was different from that of healthy people,of which 80 patients received systemic biologics.Serum homocysteine levels in patients with massive psoriasis.To explore the effect of biological agents on comorbidities caused by psoriasis,and provide a research basis for the treatment of psoriasis patients and the improvement of cardiovascular disease prognosis in the patient population.Methods:From August 2020 to August 2021,141 patients with severe plaque psoriasis（case group）admitted to the Dermatology Clinic of the Second Bethune Hospital of Jilin University were collected.Divided into abnormal metabolism group and normal metabolism group,and selected 58 healthy people（control group）who underwent physical examination in the health examination center at the same time period,and analyzed the relationship between PASI,disease duration,nail changes,and joint pain in the normal metabolism group.The relationship between serum Hcy levels was analyzed,and the differences in serum Hcy levels between the normal metabolic group and the control group and the metabolic abnormal group were analyzed.Thirty patients received adalimumab（Geleli）as group A,and 50 patients received secukinumab as group B.The efficacy was evaluated after 12 weeks of continuous administration,and the patients whose efficacy reached PASI75 were screened out.A case-control study to compare the differences in serum Hcy levels before and after treatment,and to compare the effects of secukinumab and adalimumab on serum Hcy levels in patients with psoriasis.Results:The serum Hcy level in the normal metabolism group had no statistical significance with PASI score,disease time,nail changes,and arthralgia（P>0.05）.Significance（P<0.05）.Among them,80 patients were treated with adalimumab and secukinumab and reached PASI75 for 12 weeks.The serum Hcy level after treatment was significantly different from that before treatment（P<0.05）.The effect of monoclonal antibody on serum Hcy level was not significantly different from that of adalimumab on serum Hcy level（P>0.05）.Conclusions:1.In patients with severe plaque psoriasis,there was no correlation between PASI score,disease duration,nail changes,arthralgia and serum homocysteine level.2.Serum homocysteine level in patients with severe plaque psoriasis was higher than that in healthy people.3.Among patients with severe plaque psoriasis,patients with hypertension,hyperlipidemia and diabetes have higher serum homocysteine levels.4.In patients with severe plaque psoriasis,secukinumab was more effective than adalimumab at 12 weeks.5.In patients with severe plaque psoriasis,significant remission was achieved after treatment with secukinumab and adalimumab,and the serum homocysteine level was lower than that before treatment.6.In patients with severe plaque psoriasis,significant remission was achieved after 12 weeks of treatment with secukinumab and adalimumab.The effect of secukinumab on serum homocysteine levels was similar to that of adalimumab.There was no significant difference in serum homocysteine levels.